The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Description

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Conditions

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Condition
Acute Lymphoblastic Leukemia
Intervention / Treatment

-

Contacts and Locations

Birmingham

Children's Hospital of Alabama, Birmingham, Alabama, United States, 35233

Mobile

USA Health Strada Patient Care Center, Mobile, Alabama, United States, 36604

Anchorage

Providence Alaska Medical Center, Anchorage, Alaska, United States, 99508

Mesa

Banner Children's at Desert, Mesa, Arizona, United States, 85202

Phoenix

Phoenix Childrens Hospital, Phoenix, Arizona, United States, 85016

Tucson

Banner University Medical Center - Tucson, Tucson, Arizona, United States, 85719

Little Rock

Arkansas Children's Hospital, Little Rock, Arkansas, United States, 72202-3591

Downey

Kaiser Permanente Downey Medical Center, Downey, California, United States, 90242

Loma Linda

Loma Linda University Medical Center, Loma Linda, California, United States, 92354

Long Beach

Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States, 90806

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must be less than 22 years of age at the time of study enrollment
  • * Patient must have one of the following at the time of study enrollment:
  • * Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol
  • * This includes isolated myeloid sarcoma
  • * Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS)
  • * Patient has known or suspected relapsed ALL as defined in protocol that meets one of the following criteria:
  • * Second or greater B-ALL medullary relapse, excluding KMT2Ar
  • * Any first or greater B-ALL medullary relapse involving KMT2Ar
  • * Any first or greater T-ALL medullary relapse with or without KMT2Ar
  • * Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia (MPAL) as defined in protocol
  • * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment-related AML (t-AML)
  • * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS) or treatment-related myelodysplastic syndrome (t-MDS)
  • * Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse.
  • * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML)
  • * Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse.
  • * All patients and/or their parents or legal guardians must sign a written informed consent
  • * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Ages Eligible for Study

to 22 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

LLS PedAL Initiative, LLC,

Michele S Redell, PRINCIPAL_INVESTIGATOR, Children's Oncology Group

Study Record Dates

2026-12-31